Dosing Patterns and Economic Burden of Palbociclib Drug Wastage in HR+/HER2− Metastatic Breast Cancer

Dosing Patterns and Economic Burden of Palbociclib Drug Wastage in HR+/HER2− Metastatic Breast... Adv Ther (2018) 35:768–778 https://doi.org/10.1007/s12325-018-0701-5 ORIGINAL RESEARCH Dosing Patterns and Economic Burden of Palbociclib Drug Wastage in HR+/HER22 Metastatic Breast Cancer . . . Anand A. Dalal Patrick Gagnon-Sanschagrin Rebecca Burne . . . Annie Gue ´ rin Genevie `ve Gauthier Tania Small Polly Niravath Received: February 15, 2018 / Published online: June 4, 2018 Springer Healthcare Ltd., part of Springer Nature 2018 Methods: A large US claims database was used ABSTRACT to identify postmenopausal women with HR?/ HER2- mBC who received a palbociclib-based Introduction: Targeted therapies have revolu- therapy during one of their first three lines of tionized the treatment of hormone receptor therapy for mBC between February 2015 (pal- positive/human epidermal growth factor recep- bociclib approval) and December 2015. Dosing tor 2 negative (HR?/HER2-) metastatic breast patterns (dosing modifications and sequences) cancer (mBC). However, as for many oncology were reported; a dose modification was defined drugs, the dose of targeted therapies may need as an increase/decrease of at least 25 mg daily to be adjusted over time, leading to drug compared to the preceding dose. Estimates of wastage when a dose modification is needed but drug wastage costs were based on days with the dose cannot be http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Advances in Therapy Springer Journals

Dosing Patterns and Economic Burden of Palbociclib Drug Wastage in HR+/HER2− Metastatic Breast Cancer

Loading next page...
 
/lp/springer_journal/dosing-patterns-and-economic-burden-of-palbociclib-drug-wastage-in-hr-G0ORxgYGdX
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer Healthcare Ltd., part of Springer Nature
Subject
Medicine & Public Health; Internal Medicine; Oncology; Cardiology; Rheumatology; Endocrinology; Pharmacology/Toxicology
ISSN
0741-238X
eISSN
1865-8652
D.O.I.
10.1007/s12325-018-0701-5
Publisher site
See Article on Publisher Site

Abstract

Adv Ther (2018) 35:768–778 https://doi.org/10.1007/s12325-018-0701-5 ORIGINAL RESEARCH Dosing Patterns and Economic Burden of Palbociclib Drug Wastage in HR+/HER22 Metastatic Breast Cancer . . . Anand A. Dalal Patrick Gagnon-Sanschagrin Rebecca Burne . . . Annie Gue ´ rin Genevie `ve Gauthier Tania Small Polly Niravath Received: February 15, 2018 / Published online: June 4, 2018 Springer Healthcare Ltd., part of Springer Nature 2018 Methods: A large US claims database was used ABSTRACT to identify postmenopausal women with HR?/ HER2- mBC who received a palbociclib-based Introduction: Targeted therapies have revolu- therapy during one of their first three lines of tionized the treatment of hormone receptor therapy for mBC between February 2015 (pal- positive/human epidermal growth factor recep- bociclib approval) and December 2015. Dosing tor 2 negative (HR?/HER2-) metastatic breast patterns (dosing modifications and sequences) cancer (mBC). However, as for many oncology were reported; a dose modification was defined drugs, the dose of targeted therapies may need as an increase/decrease of at least 25 mg daily to be adjusted over time, leading to drug compared to the preceding dose. Estimates of wastage when a dose modification is needed but drug wastage costs were based on days with the dose cannot be

Journal

Advances in TherapySpringer Journals

Published: Jun 4, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off